CervoMed (CRVO) Share-based Compensation (2010 - 2026)
CervoMed (CRVO) posted Share-based Compensation of $2.3 million for Q1 2026, up 669.91% sequentially from $298735.0 in Q4 2025, and up 536.82% YoY from $361167.0 in Q1 2025.
CervoMed (CRVO) Share-based Compensation (2010 - 2026) Analysis & Trends
CervoMed has reported Share-based Compensation for 17 years, with the latest figure at $2.3 million in Q1 2026.
- Quarterly Share-based Compensation rose 536.82% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (up 48.51% YoY) and the FY2025 annual result came in at $1.9 million, down 5.0% from the prior year.
- Share-based Compensation improved to $2.3 million in Q1 2026 per CRVO's latest filing, from $298735.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $2.3 million in Q1 2026 and troughed at $62252.0 in Q2 2023.
- A 5-year average of $463666.5 and a median of $278130.5 in 2022 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2023 and 2024: Share-based Compensation plunged 77.62% in 2023, then soared 829.42% in 2024.
- Over 5 years, Share-based Compensation stood at $80988.0 in 2022, then surged by 103.7% to $164972.0 in 2023, then jumped by 104.71% to $337711.0 in 2024, then retreated by 11.54% to $298735.0 in 2025, then jumped by 669.91% to $2.3 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $2.3 million, $298735.0, and $1.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | - |
| 10 | CervoMed | 26.38 Mn | 26.38 Mn | - | 362,275.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 362,275.00 |
| Jun 30, 2026 | 362,275.00 |
| Mar 31, 2026 | 2.30 Mn |
| Mar 31, 2026 | 2.30 Mn |
| Dec 31, 2025 | 298,735.00 |
| Dec 31, 2025 | 298,735.00 |
| Sep 30, 2025 | 1.50 Mn |
| Sep 30, 2025 | 1.50 Mn |
| Jun 30, 2025 | 497,015.00 |
| Jun 30, 2025 | 497,015.00 |
| Mar 31, 2025 | 361,167.00 |
| Mar 31, 2025 | 361,167.00 |
| Dec 31, 2024 | 337,711.00 |
| Dec 31, 2024 | 337,711.00 |
| Sep 30, 2024 | 271,215.00 |
| Sep 30, 2024 | 271,215.00 |
| Jun 30, 2024 | 578,581.00 |
| Jun 30, 2024 | 578,581.00 |
| Mar 31, 2024 | 218,215.00 |
| Mar 31, 2024 | 218,215.00 |